2Suppliers
10Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

electroCore, Inc. (ECOR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships
5Distinct source URLs
9High confidence
0.815Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

electroCore, Inc. Suppliers

TickerNameConfidenceEvidence
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR graph: uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that …
LLY Eli Lilly and Company 72% uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that the primary competitive factors in the primary headache markets including those f…

electroCore, Inc. Customers

TickerNameConfidenceEvidence
USGOV-DEPARTMENT-OF-DEFENSE USGOV-DEPARTMENT-OF-DEFENSE 95% USAspending awards from Department of Defense: $210,180 across 3 awards. W911S225PA206 SOLICITATION W911S225U0337: TAC-STIM; FA300225P0015 THE REQUIREMENT IS FOR TWELVE (12) TAC-STIM NON-INVASIVE VAG…
LOVELL LOVELL 92% We expect an increasing portion of our 2026 sales will be made pursuant to the non-exclusive distribution agreement with Lovell, and its contract vehicles, concentrating our customer base even furthe…
UNITED-STATES-DEPARTMENT-OF-VETERANS-AFFAIRS UNITED-STATES-DEPARTMENT-OF-VETERANS-AFFAIRS 92% The Company earns a significant amount of its revenue in the United States from the United States Department of Veterans Affairs, or VA, channel pursuant to its qualifying contract under the Federal …
VA-FACILITIES VA-FACILITIES 92% During the years ended December 31, 2025 and 2024, revenue from VA facilities pursuant to the terms and conditions of our qualifying contract under the FSS and open market sales represented 71.2% and…
NHS-ENGLAND NHS-ENGLAND 85% any changes in recommendation or pricing may adversely impact our ability to work with NHS England on the MTFM program, which could have an adverse impact on our business in the United Kingdom.
UNITED-KINGDOM-NATIONAL-HEALTH-SERVICE UNITED-KINGDOM-NATIONAL-HEALTH-SERVICE 85% During the three months ended March 31, 2026 and 2025, one facility accounted for more than 10% of net sales from the United Kingdom National Health Service ("NHS").
LLY Eli Lilly and Company 72% uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that the primary competitive factors in the primary headache markets including those f…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR graph: Reciprocal relationship from LLY grap…
ALPHABET-INC-AMAZON-COM-INC-APPLE-INC-SAMSUNG-EL ALPHABET-INC-AMAZON-COM-INC-APPLE-INC-SAMSUNG-EL 62% sts and decrease our operating margins, thereby adversely impacting our business, financial condition, and results of operations. Some of the world’s largest technology companies that have not histor…
CO-LLC CO-LLC 62% Item 1A. Risk Factors. RISK FACTORS You should carefully consider the following risk factors, in addition to the other information in this Annual Report, including the section of this Annual Report t…

electroCore, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ECOR-DEBT Debt stack $6.1M 90% Market cache reports total debt of $6.1M.
ECOR-DEBT-9216 Warrants outstanding: 44000 90% xbrl warrant detail from xbrl 2026-04-30.
ECOR-DEBT-9217 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-12-31.

electroCore, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for electroCore, Inc..

electroCore, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for electroCore, Inc..

electroCore, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
LLY Eli Lilly and Company 100.00 1 ['customer', 'supplier']
LOVELL LOVELL 63.48 1 ['receiving']
AXSM Axsome Therapeutics, Inc. 50.00 2
BIOA BioAge Labs, Inc. 50.00 2
FHTX Foghorn Therapeutics Inc. 50.00 2
BEAM Beam Therapeutics Inc. 50.00 2
AKTS Aktis Oncology, Inc. 50.00 2
AMPH Amphastar Pharmaceuticals, Inc. 50.00 2
HMDCF HUTCHMED (China) Ltd 50.00 2
EDSA Edesa Biotech, Inc. 50.00 2
LGNZZ LIGAND PHARMACEUTICALS INC 50.00 2
BCYC Bicycle Therapeutics plc 50.00 2
HCM HUTCHMED (China) Limited 50.00 2
LGND Ligand Pharmaceuticals Incorporated 50.00 2
ATOS Atossa Therapeutics, Inc. 50.00 2
DSGN Design Therapeutics, Inc. 50.00 2
NVO Novo Nordisk A/S 50.00 2
CTMX CytomX Therapeutics, Inc. 50.00 2
GYRE Gyre Therapeutics, Inc. 50.00 2
DAWN Day One Biopharmaceuticals Inc 50.00 2
🔐
ECOR
Unlock ECOR Supply Chain Data
Verified relationships include:
LLYEli Lilly and CompanySupplier72%
LLYEli Lilly and CompanySupplier72%
USGOV-DEPARTMENT-OF-DEFENSEUSGOV-DEPARTMENT-OF-DEFENSECustomer95%
LOVELLLOVELLCustomer92%
+11 more relationships locked
Subscribe, View plans →